Naphthalimide Platinum(IV) Compounds as Antitumor Agents with Dual DNA Damage Mechanism to Overcome Cisplatin Resistance

Wang, Qingpeng; Li, Guoshuai; Liu, Zhifang; Tan, Xiaoxiao; Ding, Zhuang; Ma, Jing; Li, Lanjie; Li, Dacheng; Han, Jun

doi:10.1002/ejic.201800799

Cited by 14 publications

(8 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The fluorescence displacement experiments of EB‐DNA are widely used to investigate the intercalation of DNA intercalators. [ 27 ] The synthesized Pt (IV) was pretreated with GSH and added to the EB‐DNA solution for fluorescence titration. Notably, EB and EB‐DNA as controls were also pretreated with GSH to control for experimental variables.…”

Section: Resultsmentioning

confidence: 99%

Synthesis, characterization, and antitumor biological evaluation of novel fluorine‐containing platinum (IV) complexes

Chen

Zhao

Yang

et al. 2022

Applied Organom Chemis

View full text Add to dashboard Cite

A series of antitumor platinum (IV) complexes based on ammonia and fluoropyridine carrier groups with biotin and chloride ions as axial groups have been designed and synthesized in this paper. The structures of platinum (IV) complexes were fully characterized by 1H NMR, ESI‐MS, and IR. Such Pt (IV) complexes have certain tumor targeting properties, and the Pt (II) complexes released in the reducing microenvironment could combine with DNA. Compared with cisplatin, complexes S3 and S4 exhibited similar cytotoxicity against SW480, HCT116, and HepG2 cancer cell lines according to in vitro antitumor activity evaluation. Particularly, Complex S2 showed 1.5–3.0 times higher cytotoxicity than cisplatin and picoplatin against selected cell lines. According to the structure–activity relationship, the introduction of fluorine atoms and axial chloride has an important influence on the strong cytotoxic activity of Pt (IV) complex. In addition, the axial biotin molecule increased the targeting of the complex to tumor cells. Overall, the novel fluorine‐containing Pt (IV) complex S2 is an attractive antitumor lead compound with further research value.

show abstract

Section: Resultsmentioning

confidence: 99%

Synthesis, characterization, and antitumor biological evaluation of novel fluorine‐containing platinum (IV) complexes

Chen

Zhao

Yang

et al. 2022

Applied Organom Chemis

View full text Add to dashboard Cite

show abstract

“…The synthetic procedures for oxoplatins O1-O3 are given in the ESI † according to procedures reported in our previous work. 36,37 3.1.2.1 Preparation of compound 1. To a solution of FLP 10 (54 mg, 0.22 mmol) and TBTU (71 mg, 0.22 mmol) in dry DMF 5 mL was added TEA (30 μL, 0.22 mmol) and stirred for 10 min at room temperature.…”

Section: Methodsmentioning

confidence: 99%

“…In addition, the combination of PD-L1 inhibitory drugs with platinum-based chemotherapy showed significantly increased therapeutic effects, and has emerged as a promising chemotherapeutic option especially in advanced cancers. 20,29,32 Inspired by the above conditions and as a constitution of our interest in developing novel antitumor platinum(IV) agents, [33][34][35][36][37][38][39] FLP was incorporated into the platinum (IV) system as a functional group targeting both COX and PD-L1 to form complexes 1-4 (Fig. 2), with the expectation that the target complexes would display prominent antiproliferative and anti-metastatic activities by modulating the inflammation and immune response in TME.…”

Section: Introductionmentioning

confidence: 99%

Development of a series of flurbiprofen and zaltoprofen platinum(iv) complexes with anti-metastasis competence targeting COX-2, PD-L1 and DNA

Zhao

et al. 2022

Dalton Trans.

Self Cite

View full text Add to dashboard Cite

show abstract

“…The synthetic procedures for oxoplatin O1–O2 were supplied in the supporting information according to procedures reported in the literature. 42 , 44 …”

Section: Methodsmentioning

confidence: 99%

Albumin-encapsulated Nanoparticles of Naproxen Platinum(IV) Complexes with Inflammation Inhibitory Competence Displaying Effective Antitumor Activities in vitro and in vivo

Li¹,

Chen²,

Wang³

et al. 2021

IJN

Self Cite

View full text Add to dashboard Cite

Background Platinum(IV) complexes with inflammation inhibitory properties are much favored in improving antitumor activities. Nanodrug-delivery system as a preferable measure for antitumor therapy are widely explored in platinum(IV) drug delivery. Purpose The aim for this study was to develop novel bovine serum albumin (BSA) nanoparticles (NPs) based on naproxen platinum(IV) complexes to display a synergistic antitumor mechanism targeting cyclooxygenase-2 (COX-2), metalloproteinase-9 (MMP-9) and inducible nitric oxide synthase (iNOS). Methods Herein, we reported the preparation of two BSA NPs of naproxen platinum(IV) complexes, and their antitumor activities were investigated in vitro and in vivo. Results Both NPs possessed relatively uniform size and good stability for 30 days in aqueous solution. They exhibited prominent antitumor activities in vitro, and showed great potential in reversing drug resistance. Furthermore, these two NPs played superior tumor growth suppression in vivo in contrast to the free compounds, which were comparable to that of cisplatin and oxaliplatin, but induced lower toxic influences than platinum(II) drugs especially to spleen and liver. Moreover, the naproxen platinum(IV) NPs could decrease tumor inflammation targeting COX-2, MMP-9 and iNOs, and decreasing NO production, which would be in favor of enhancing the antitumor competence, and reducing toxicity. Conclusion Taken together, BSA NPs of naproxen platinum(IV) complexes demonstrated a powerful antitumor efficacy in vitro and in vivo. The platinum(IV) NPs with inflammation inhibitory competence targeting multiple enzymes reported in this work afford a new strategy for the development of antitumor therapy to overcome drawbacks of clinical platinum(II) drugs.

show abstract

Naphthalimide Platinum(IV) Compounds as Antitumor Agents with Dual DNA Damage Mechanism to Overcome Cisplatin Resistance

Cited by 14 publications

References 40 publications

Synthesis, characterization, and antitumor biological evaluation of novel fluorine‐containing platinum (IV) complexes

Synthesis, characterization, and antitumor biological evaluation of novel fluorine‐containing platinum (IV) complexes

Development of a series of flurbiprofen and zaltoprofen platinum(iv) complexes with anti-metastasis competence targeting COX-2, PD-L1 and DNA

Albumin-encapsulated Nanoparticles of Naproxen Platinum(IV) Complexes with Inflammation Inhibitory Competence Displaying Effective Antitumor Activities in vitro and in vivo

Contact Info

Product

Resources

About